Time filter

Source Type

Chalkída, Greece

Galyfos G.,General Hospital of Chalkis | Palogos K.,General Hospital of Chalkis | Kavouras N.,General Hospital of Chalkis
Scandinavian Journal of Infectious Diseases | Year: 2014

The injection of drugs into the neck is unusual and thrombosis of the internal jugular vein can be a rare clinical presentation with a high risk for severe complications. We report a case of a 31-year-old male intravenous drug user presenting with fever, shortness of breath and right neck oedema. Laboratory studies revealed elevated inflammation parameters. X-ray imaging revealed a broken syringe needle inside the soft tissues of the neck. Computed tomography (CT) scans of the thorax and brain were unremarkable, while cervical CT showed a fully thrombosed, right internal jugular vein. Intravenous antibiotics were initiated, and modified after identification of an anaerobic Gram-negative oropharynx-derived pathogen (Fusobacterium necrophorum). The patient was discharged after resolution of symptoms under treatment. Septic internal jugular vein thrombosis should always be included in the differential diagnosis of local neck inflammation and systemic sepsis in intravenous drug users. Prompt and aggressive antibiotic treatment is vital, whereas the role of anticoagulation therapy is not definitely known. © 2014 Informa Healthcare.

Terpos E.,National and Kapodistrian University of Athens | Katodritou E.,Theagenion Cancer Center | Roussou M.,National and Kapodistrian University of Athens | Pouli A.,Saint Savvas Anticancer Hospital | And 11 more authors.
European Journal of Haematology | Year: 2010

Objectives: High serum lactate dehydrogenase (LDH) is associated with features of advanced disease and inferior survival in multiple myeloma. It is however unclear whether LDH adds to the prognostic value of International Staging System (ISS) and whether it retains its prognostic significance in patients who are exposed to novel agent-based therapies. Patients/Methods: To address these issues we analyzed 996 consecutive symptomatic patients who were included in the database of the Greek Myeloma Study Group and received frontline treatment between January 1, 1995 and December 31, 2008. Results: The median overall survival (OS) of all patients was 40 months with a clear improvement in those who started treatment after January 1, 2000 (49 vs. 31 months; P < 0.01). A multivariate model showed that LDH, ISS, performance status, age and platelet counts had an independent prognostic value for OS (P < 0.001 for all parameters). The median OS of patients with high (11% of patients) and normal LDH was 15 vs. 44 months (P < 0.001). High LDH was associated with inferior OS within all ISS groups: 22 vs. 76 months for high and normal LDH groups, respectively, in ISS-1 (P < 0.01); 11 vs. 40 months in ISS-2 (P < 0.001) and 17 vs. 27 months in ISS-3 (P < 0.01). The median OS of high and normal LDH groups among patients who received novel agents was 21 vs. 51 months, respectively (P < 0.001). Conclusions: Lactate dehydrogenase is a readily available and inexpensive variable, which has a major impact on the survival of myeloma patients even when they belong to a low or intermediate ISS subgroup and even when they receive novel agent-based therapies. © 2010 John Wiley & Sons A/S.

Ximeri M.,University of Crete | Galanopoulos A.,G. Gennimatas Hospital | Klaus M.,University of Crete | Parcharidou A.,Red Cross | And 12 more authors.
Haematologica | Year: 2010

Background: Lenalidomide improves erythropoiesis in patients with low/intermediate-1 risk myelodysplastic syndrome and interstitial deletion of the long arm of chromosome 5 [del(5q)]. The aim of this study was to explore the effect of lenalidomide treatment on the reserves and functional characteristics of bone marrow hematopoietic progenitor/precursor cells, bone marrow stromal cells and peripheral blood lymphocytes in patients with low/intermediate-1 risk myelodysplastic syndrome with del(5q). Design and Methods: We evaluated the number and clonogenic potential of bone marrow erythroid/myeloid/ megakaryocytic progenitor cells using clonogenic assays, the apoptotic characteristics and adhesion molecule expression of CD34+ cells by flow cytometry, the hematopoiesis-supporting capacity of bone marrow stromal cells using long-term bone marrow cultures and the number and activation status of peripheral blood lymphocytes in ten patients with low/intermediate-1 risk myelodysplastic syndrome with del(5q) receiving lenalidomide. Results: Compared to baseline, lenalidomide treatment significantly decreased the proportion of bone marrow CD34+ cells, increased the proportion of CD36+/GlycoA+ and CD36-/GlycoA+ erythroid cells and the percentage of apoptotic cells within these cell compartments. Treatment significantly improved the clonogenic potential of bone marrow erythroid, myeloid, megakaryocytic colony-forming cells and increased the proportion of CD34+ cells expressing the adhesion molecules CD11a, CD49d, CD54, CXCR4 and the SLAM antigen CD48. The hematopoiesis-supporting capacity of bone marrow stroma improved significantly following treatment, as demonstrated by the number of colony-forming cells and the level of stromal-derived factor-1α and intercellular adhesion molecule-1 in long-term bone marrow culture supernatants. Lenalidomide treatment also increased the proportion of activated peripheral blood T lymphocytes. Conclusions: The beneficial effect of lenalidomide in patients with lower risk myelodysplastic syndrome with del(5q) is associated with significant increases in the proportion of bone marrow erythroid precursor cells and in the frequency of clonogenic progenitor cells, a substantial improvement in the hematopoiesis-supporting potential of bone marrow stroma and significant alterations in the adhesion profile of bone marrow CD34+ cells. ©2010 Ferrata Storti Foundation.

Dontas I.A.,National and Kapodistrian University of Athens | Tsolakis A.I.,National and Kapodistrian University of Athens | Khaldi L.,National and Kapodistrian University of Athens | Patra E.,General Hospital of Chalkis | Lyritis G.P.,National and Kapodistrian University of Athens
Journal of the American Association for Laboratory Animal Science | Year: 2010

Insufficient wear of rodent incisors often results in malocclusion and rapid tooth elongation. This condition may go undetected for a prolonged time and have a negative effect on affected animals' welfare. Dental overgrowth can lead to undernutrition due to chronic difficulty in feeding and may cause trauma to the surrounding tissues, potentially ultimately resulting in death. Here we describe the increased incidence of malocclusion observed during a longitudinal study of the normal growth and aging of Wistar rats. Histologic examination of the temporomandibular joint of affected animals did not reveal any inflammatory or degenerative changes. Because no environmental factor could be implicated in the condition, we considered that aging or genetic factors were responsible for its appearance. We conclude that special attention should be given to the potential appearance of malocclusion during long-term rodent studies, because its incidence may adversely affect the animals' health and general wellbeing. Copyright 2010 by the American Association for Laboratory Animal Science.

Galyfos G.,General Hospital of Chalkis | Karantzikos G.A.,General Hospital of Chalkis | Kavouras N.,General Hospital of Chalkis | Sianou A.,National and Kapodistrian University of Athens | And 2 more authors.
Indian Journal of Surgery | Year: 2016

Extraosseous Ewing sarcomas (EESs) are rare tumours originating from soft tissues. Their clinical picture depends mainly on the primary site of the sarcoma. Patient characteristics and outcomes seem to be different in EES compared to patients with skeletal Ewing sarcoma, with implications for patient care and prognosis. However, multimodality therapeutic strategies are recommended for all types of the Ewing tumour family. The available diagnostic tools include ultrasonographic evaluation and computed tomography (CT) or magnetic resonance imaging as well as histopathologic and immunohistochemical tissue examination. Several histologic and genetic biomarkers have been established, although their utilization needs to be further tested by larger prospective studies. Regarding localized disease, the recommended treatment remains surgery. However, chemotherapy can be added to achieve improved survival, with neoadjuvant regimens showing more promising results than adjuvant regimens. Radiotherapy is an option to obtain local control, although its complications have reduced its utilization. In metastatic or recurrent disease, systematic chemotherapy improves survival. © 2015, Association of Surgeons of India.

Discover hidden collaborations